Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
7 search results for:

Idelalisib 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 23-03-2017 | Lymphoma | News | Article

    Excessive toxicity halts idelalisib, lenalidomide plus rituximab lymphoma trials

    Two phase 1 trials investigating the safety and efficacy of combined idelalisib, lenalidomide, and rituximab in patients with relapsed and refractory follicular and mantle cell lymphoma have been stopped early due to excessive toxicity.

    Published in:
    Lancet Haematol 2017; Advance online publication
  2. 18-10-2022 | PI3K inhibitors | News | Article

    Meta-analysis reveals high risk for cutaneous AEs with PI3K inhibitors

    The meta-analysis included 16 phase 2 or 3 RCTs that evaluated the efficacy of PI3K inhibitors – such as alpelisib, idelalisib, pictilisib, sonolisib, and taselisib – in patients with malignant conditions and reported on cutaneous AEs.

    Author:
    Shreeya Nanda
    Published in:
    JAMA Oncol 2022; doi:10.1001/jamaoncol.2022.4327
  3. 28-07-2017 | Chronic lymphocytic leukemia | Article

    Targeting B Cell Signaling in Chronic Lymphocytic Leukemia

    The authors provide an overview of recent work on developing therapies targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia and highlight future avenues for development. Arnason JE, Brown JR. Curr Oncol Rep 2017; 19: 61. doi:10.1007/s11912-017-0620-7

  4. 02-03-2018 | Hematologic cancers | News | Article

    Next-generation PI3Kδ inhibitor umbralisib warrants further investigation

    Owen O’Connor (Columbia University Medical Center, New York, USA) and colleagues explain that umbralisib is structurally distinct from other PI3Kδ inhibitors, such as idelalisib and duvelisib, with improved isoform selectivity, minimal off-target cytochrome P450 inhibition, and a plasma exposure concentration that makes it suitable for once-daily dosing.

    Published in:
    Lancet Oncol 2018; Advance online publication
  5. 14-03-2017 | Lymphoma | Case report | Article

    SLL and CLL

    Alternatives include ibrutinib, idelalisib ± rituximab, lenalidomide, among others.

    Author:
    Tanya Siddiqi, Steven T Rosen
  6. 29-12-2016 | Lymphoma | Article

    The landscape of new drugs in lymphoma

    Idelalisib is approved for the treatment of patients with relapsed CLL, small lymphocytic lymphoma (SLL), or FL.

    Author:
    Anas Younes, Stephen Ansell, Nathan Fowler, Wyndham Wilson, Sven de Vos, John Seymour, Ranjana Advani, Andres Forero, Frank Morschhauser, Marie Jose Kersten, Kensei Tobinai, Pier Luigi Zinzani, Emanuele Zucca, Jeremy Abramson, Julie Vose
  7. 21-04-2017 | Lymphoma | Feature | Article

    Lymphoma in practice: Professor Anas Younes speaks to medwireNews

    In some cases, such as with idelalisib, uncommon but serious toxicities have arisen after the agent was approved, he explains.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.